Log in to search using one of your social media accounts:

 

Estrogenic regulation of skeletal muscle proteome: a study of premenopausal women and postmenopausal MZ cotwins discordant for hormonal therapy

Summary Female middle age is characterized by a decline in skeletal muscle mass and performance, predisposing women to sarcopenia, functional limitations, and metabolic dysfunction as they age. Menopausal loss of ovarian function leading to low circulating level of 17β‐estradiol has been suggested as a contributing factor to aging‐related muscle deterioration. However, the underlying molecular mechanisms remain largely unknown and thus far androgens have been considered as a major anabolic hormone for skeletal muscle. We utilized muscle samples from 24 pre‐ and postmenopausal women to establish proteome‐wide profiles, associated with the difference in age (30–34 years old vs. 54–62 years old), menopausal status (premenopausal vs. postmenopausal), and use of hormone replacement therapy (HRT; user vs. nonuser). None of the premenopausal women used hormonal medication while the postmenopausal women were monozygotic (MZ) cotwin pairs of whom the other sister was current HRT user or the other had never used HRT. Label‐free proteomic analyses resulted in the quantification of 797 muscle proteins of which 145 proteins were for the first time associated with female aging using proteomics. Furthermore, we identified 17β‐estradiol as a potential upstream regulator of the observed differences in muscle energy pathways. These findings pinpoint the underlying molecular mechanisms of the metabolic dysfunction accruing upon menopause, thus having ...
Source: Aging Cell - Category: Cytology Authors: Tags: Original Article Source Type: research

Related Links:

Authors: Gambacciani M, Biglia N, Cagnacci A, DI Carlo C, Caruso S, Cicinelli E, DE Leo V, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A Abstract In the last decade the risk benefits ratio of HRT has been reevaluated mainly in tens of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausel Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society,...
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
CONCLUSION: Until additional studies are performed, the risks and benefits must be weighed on an individual basis with consideration of prophylaxis when a decision is made to continue these medications in the perioperative period. Part of this decision making includes the risk of fetal harm in an unwanted pregnancy in preparation for nonobstetric surgery versus an increased risk of venous thromboembolism. PMID: 28969534 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
According to a study published inJAMA, women who take hormone replacement therapy may be no more likely to die prematurely than women who do not take hormones.Reuters 
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
For decades now, women navigating menopause have been buffeted by shifting research findings on the risks and possible benefits of hormone-replacement therapy. Now, a landmark clinical trial that followed more than 27,000 subjects for roughly 18 years has offered some conclusive evidence that neither...
Source: Los Angeles Times - Science - Category: Science Authors: Source Type: news
(Reuters Health) - Women who take hormone replacement therapy (HRT) to ease menopause symptoms like hot flashes and night sweats may be no more likely to die prematurely than women who don ’t take hormones, a new study suggests.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The pendulum has swung from one extreme to the other when it comes to hormone replacement therapy (HRT) to treat symptoms of menopause. At first, the replacement hormones—mostly a combination of estrogen and progestin to replace what the body stops making after menopause—were seen as a panacea. Doctors thought they could not only relieve hot flashes and night sweats, but also prevent chronic aging diseases like heart problems and weakening bones. But studies then found that the supplement hormones could lead to a higher risk of breast cancer—and that they didn’t protect the heart after all. In the l...
Source: TIME.com: Top Science and Health Stories - Category: Consumer Health News Authors: Tags: Uncategorized Drugs estrogen Hormone Therapy hormones for menopause hot flashes night sweats progestin Reproductive Health treating menopause Source Type: news
Dr JoAnn Manson is the lead author of a new report that examined all-cause and cause-specific mortality among women who have taken hormone replacement therapy for menopausal symptoms.Medscape Ob/Gyn
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news
Does genetic testing for ERα gene polymorphisms provide new possibilities of treatment for cognitive function disorders in postmenopausal women? Arch Med Sci. 2017 Aug;13(5):1224-1232 Authors: Gujski M, Pinkas J, Wierzbińska-Stępniak A, Owoc A, Bojar I Abstract It is commonly considered that cognitive abilities decrease with age, especially with respect to processing and psychomotor speed. It is an interesting issue whether, apart from the ageing process, the undergoing of menopause itself deteriorates cognitive functions, compared to women at reproductive age. Hopes for improvement of cognitiv...
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
Abstract Several lines of investigation have shown a protective role for estrogen in Alzheimer's disease through a number of biological actions. This review examines studies of the role of estrogen-related factors in age at onset and risk for Alzheimer's disease in women with Down syndrome, a population at high risk for early onset of dementia. The studies are consistent in showing that early age at menopause and that low levels of endogenous bioavailable estradiol in postmenopausal women with Down syndrome are associated with earlier age at onset and overall risk for dementia. Polymorphisms in genes associated wi...
Source: Free Radical Biology and Medicine - Category: Biology Authors: Tags: Free Radic Biol Med Source Type: research
More News: Cytology | Estradiol | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Men | Menopause | Ovaries | Study | Women